🧵🧵🧵
The new paper “COVID-19 is ‘Airborne AIDS’: provocative oversimplification, emerging science, or something in between?” in AJPM Focus addresses why some researchers have compared COVID-19 and HIV/AIDS.
Both viruses can drive long-term immune dysfunction, tissue persistence and systemic impact.
SARS-CoV-2 isn’t just a short-term respiratory virus. For many, it leaves lasting immune changes and systemic impacts. Both Covid and HIV viruses can lead to immune dysfunction, tissue reservoir persistence, accelerated aging and neurological impacts.
2/
Both viruses can:
- Deplete or exhaust T cells
- Drive chronic inflammation
- Weaken immune defenses
- Increase vulnerability to opportunistic infections
3/
They both persist in the body. HIV integrates into the DNA while
Covid has been detected in the brain, gut, lungs and other tissues months after infection
4/
They both accelerate aging in the body. HIV leads to gradual immune exhaustion over years. Covid can trigger aging markers within months and repeat infections may compound the effects
5/
Both trigger neuro inflammatory processes that can cause cognitive decline
6/
There are also important differences:
- HIV is bloodborne. COVID is airborne.
- HIV acts slowly. Covid can disrupt immune systems within weeks.
- Long COVID involves vascular and clotting pathology not seen in HIV.
- HIV has effective treatments. Long COVID does not.
7/
Calling it “airborne AIDS” underscores the urgency of dealing with COVID- a highly transmissible airborne virus capable of immune disruption that can reshape public health.
8/
The authors call for
- Ongoing infection control
- More research on viral persistence and immune dysfunction
- Better recognition of chronic post-viral illness
- Applying lessons learned from the AIDS epidemic to COVID
9/
HIV taught us a lot about stigma, inequity and the consequences of delayed action.
COVID calls for the same level of attention and urgency, with the hope that we can respond with more wisdom, clarity and empathy this time
10/10
• • •
Missing some Tweet in this thread? You can try to
force a refresh
If you contract COVID and are unable to take Paxlovid due to med interactions or liver/kidney issues, you may be able to access their new COVID anti-viral Ibuzatrelvir, now in phase 3 clinical trials
Ibuzatrelvir is a second-generation COVID antiviral that simplifies COVID-19 treatment by removing Ritonavir. Ritonavir is the boosting agent used in Paxlovid that gives it the bad taste and the drug/organ risks.
2/
They are enrolling adolescent (12-18yrs) and adult participants over the age of 18.
The study is targeting individuals at higher risk of developing severe COVID-19 or complications from COVID-19. Criteria are listed here:
3/pfizerclinicaltrials.com/nct06679140-co…
🧵🧵🧵
Many people with Long COVID have severe GI symptoms, yet their endoscopies and scans often come back “normal.” These are Disorders of gut–brain interaction (DGBI), conditions where the brain’s signals to the gut and the gut’s nerves misfire, disrupting digestion.
1/
DGBI are not caused by ulcers or polyps. They result from disrupted communication between the brain, autonomic nerves and gut. This impacts motility, sensation and gastric secretions. Examples of DGBI can include gastroparesis, functional dyspepsia, IBS and chronic constipation.
2/
We are very fortunate to have the Mass General Center for Neurointestinal Health, which is dedicated to DGBI. This center brings together advanced motility testing, nutrition and behavioral therapies, surgical care and a deep research program for both adults and children.
Here is a roundup of what's in the pipeline for #LongCOVID.
Trials are testing antivirals, immune modulators, brain fog treatments, microclot therapies and more. 1/
Y’all. I have a longggg fuse, I promise I do. It takes a lot to anger me. But it’s happening today with people accusing @PutrinoLab of advocating for graded exercise.
Nothing could be further from the truth and you all should know better if you know him and/or read the full manual
1/
The Infection-Associated Chronic Illnesses Provider Manual is a LOVE LETTER to everyone who has been suffering and misunderstood and gaslit. It’s 169 pages of explaining in DETAIL the complexity of your bodies and the risks of traditional exercise programs to help other providers better understand you
2/
There are multiple many MANY examples of explanations about traditional exercise being harmful. No one can come away from reading this manual thinking they are advocating graded exercise 3/
🧵🧵🧵Here is the data from our July 2025 referrals to our Long COVID clinic at Brigham and Women’s Hospital
1/
96 referrals received in July.
This brings our total since opening in 2021 to almost 6,000.
Still working through intakes, but 65 are scheduled with providers so far.
2/
Referrals to specialists in our program- Most patients see more than one specialist. These numbers are preliminary and will greatly increase as patients move through their intakes and initial appts
3/
🧵Last week, Dr. Lael Yonker's study using larazotide to treat gut permeability was published. This study was conducted on children with MISC from COVID-19. The study showed that the Larazotide helped clear lingering spike protein from the blood more quickly, eased gut symptoms faster and sped up recovery compared to placebo. The drug was well tolerated and is now being studied as a possible treatment for long COVID. science.org/doi/10.1126/sc…
1/
Larazotide works by blocking the action of a protein called zonulin, which helps control how “tight” or “loose” the spaces are between cells in the gut lining (called tight junctions).
2/
When zonulin levels go up, often in response to irritants, infections, gluten or inflammation, it signals those tight junctions to open. This can make the gut more “leaky,” allowing harmful substances like viral particles, toxins or inflammatory molecules to pass into the bloodstream.
3/